GXO Appoints Richard Cawston as Chief Revenue Officer
GREENWICH, Conn., and LONDON, U.K., Jan. 11, 2024 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract […]
New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%
First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears […]
TSX News -
Solaris Announces $130 Million Strategic Investment by Zijin Mining Group
VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) […]
Great Pacific Gold Receives Additional High-Grade Assay on Alteration Halo Around Comet Discovery Expanding Intercept, Appoints Dr. Chris Muller to Board and Grants RSU and Stock Options
VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) — Great Pacific Gold Corp. (“Great Pacific Gold,” “GPAC,” or the “Company”) […]
Quanta and Ambarella Expand Strategic Partnership to Innovate Broader Range of Cutting-Edge AI Solutions
TAOYUAN CITY, Taiwan and SANTA CLARA, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) — Quanta Computer Inc., a trailblazer in advanced […]
TSX News -
Aura Announces Q4 2023 Production Results, 7% above Q3 2023
ROAD TOWN, British Virgin Islands, Jan. 10, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: […]
Vortex Energy Commences Drill Trail Clearing Process at the Robinsons River Salt Project, Newfoundland & Labrador
VANCOUVER, British Columbia, Jan. 10, 2024 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) […]
AIMイムノテック (AIM ImmunoTech)、膵臓がん治療を目的としたアストラゼネカ (AstraZeneca) のImfinzi® (デュルバルマブ) との併用によるAmpligen® (リンタトリモド) を評価する第Ib/II相試験の登録開始を発表
オランダ、ロッテルダムのエラスムス医療センター (Erasmus Medical Center) で、間もなく最初の登録および最初の被験者への投与を予定 経営陣による同発表とその意義についての説明は動画を参照されたい。 フロリダ州オカラ発, Jan. 11, 2024 (GLOBE NEWSWIRE) — AIMイムノテック (AIM ImmunoTech Inc.) [...]
AIM ImmunoTech 宣布开展评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi® (durvalumab) 联合用药治疗胰腺癌疗效的 1b/2 期研究的开放招募
首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行 管理层在以下视频中对本公告及其意义进行了讨论，视频链接为：视频 奥卡拉，佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.（美国 NYSE：AIM）（简称“AIM”或“公司”）今日宣布，在 Erasmus [...]
TSX News -
Middlefield Announces Intention to Convert International Clean Power Dividend Fund Into Infrastructure Dividend Split Corp
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Middlefield Limited (the “Manager”), the manager of International Clean Power Dividend Fund (“CLP”), […]
